Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and cardiovascular risk reduction. Developed by Eli Lilly as a predecessor to tirzepatide. One of the most prescribed GLP-1 agonists globally.
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
A GLP-1 analog fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. Activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
- Type 2 diabetes
- Cardiovascular risk reduction
- Moderate weight loss
- Blood sugar regulation
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis (rare)
- Thyroid C-cell tumors (animal studies)
- Injection site reactions
- Hypoglycemia when combined with insulin
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
FDA-approved as Trulicity (2014) for type 2 diabetes and cardiovascular risk reduction (REWIND trial). Once-weekly injection via single-dose pen. One of the top-selling GLP-1 drugs globally.
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.